Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Oncogene. 2018 Mar 15;37(23):3151–3165. doi: 10.1038/s41388-018-0178-3

Figure 4. miR-21 in CD8+ T cells and CD4+ T cells.

Figure 4

CD8+ T cells and CD4+ T cells were treated with antibodies against CD3 and CD28 for cytokine and cytolytic granzyme B (GzmB) production. (a and b) Representative graphs of flow cytometry analyses of CD8+ T cells with 24 h treatment (a) and CD4+ T cells with 12 h or 24 h treatment (b) treated with antibodies against CD3 and CD28. (c, d, e) Fractions of GzmB-positive CD8+ T cells (c), TNF-α-positive CD8+ T cells (d), and TNFα-positive CD4+ T cells (e). n = 3 biological isolates for both WT and miR-21−/− groups. *P ≤ 0.05, ***P ≤ 0.001.